Izhak et al. [197] revealed in their study that it is the predominantly expressed chemokine within primary tumors of prostate cancer patients and its production ultimately triggers a collapse of immunological tolerance to CCL2. This evidence concerns the gene CCL2 and Familial prostate cancer.